SRPT News and Press, Sarepta Therapeutics Inc. From 02/04/26

– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medic...

2026-01-26 13:32:20 ET Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy January 26, 2026 8:30 AM EST... Read the full article on Seeking Alpha For further details see: Sarepta Therapeutics...

2026-01-26 08:55:36 ET More on Sarepta Therapeutics Sarepta Preliminary Results: Not What The Market Wanted To Hear Sarepta Therapeutics: Is Elevidys A Bust? Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow ...

A t a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline relative to the propensity...

2026-01-23 17:55:25 ET More on Sarepta Therapeutics Sarepta Preliminary Results: Not What The Market Wanted To Hear Sarepta Therapeutics: Is Elevidys A Bust? Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 3-year topline functional results from patients treated in P...

2026-01-21 22:50:00 ET The market had no love for Sarepta Therapeutics (NASDAQ: SRPT) and Teladoc Health (NYSE: TDOC) last year, as both companies lagged broader equities and lost significant market value. This might make them attractive at current levels if there are good r...

2026-01-16 11:18:11 ET Thesis Sarepta Therapeutics, Inc. ( SRPT ) guided preliminary 4Q25 and FY25 sales a few days ago, and as you know, the figures were a bit below Wall Street’s expectations. It was an all-around softer-than-expected 4Q25 performance. The company e...

2026-01-16 09:25:44 ET It has been roughly seven months since my previous Sarepta Therapeutics ( SRPT ) article titled “Sarepta Therapeutics: Rebuilding the Thesis After Hitting Rock Bottom.” At that time, SRPT was in collapse after ELEVIDYS had become a regulatory...

2026-01-12 14:36:00 ET Sarepta Therapeutics, Inc. (SRPT) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 12:00 PM EST... Read the full article on Seeking Alpha For further details see: Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healt...